Skip to main content
. 2017 Jul 25;80(3):599–608. doi: 10.1007/s00280-017-3380-z

Fig. 1.

Fig. 1

RAISE study design aIrinotecan: 180 mg/m2; Folinic acid: 400 mg/m2; 5-flurouracil: 400 mg/m2 bolus followed by 400 mg/m2 given as a continuous infusion over 48 hours FOLFIRI, folinic acid, 5-fluorouracil, and irinotecan; IG immunogenicity; IV intravenous; ORR objective response rate; PFS progression-free survival; PK pharmacokinetics; PRO patient-reported outcomes; RAM ramucirumab